Mark Coleman - 28 May 2024 Form 4 Insider Report for Axsome Therapeutics, Inc. (AXSM)

Role
Director
Signature
/s/ Herriot Tabuteau, M.D., Attorney-in-Fact
Issuer symbol
AXSM
Transactions as of
28 May 2024
Net transactions value
-$789,107
Form type
4
Filing time
29 May 2024, 20:11:32 UTC
Previous filing
15 Sep 2023
Next filing
11 Jun 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AXSM Common Stock Sale $394,775 -5,249 -21% $75.21 19,848 28 May 2024 Direct F1, F2, F3
transaction AXSM Common Stock Sale $394,333 -5,248 -26% $75.14 14,600 29 May 2024 Direct F1, F2, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Such transaction was pursuant to a pre-approved 10b5-1 plan.
F2 Represents the sale of underlying shares of previously exercised stock options.
F3 Represents the weighted average sale price of a series of open market transactions with sale prices ranging between $75.00 and $75.88.
F4 Represents the weighted average sale price of a series of open market transactions with sale prices ranging between $75.00 and $75.90.